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Lessons From the Development of New Adenosine
A2A Receptor Agonists*
James E. Udelson, MD, FACC
Boston, MassachusettsA class of agonists relatively specific for the aden-
osine A2A receptor is under development for phar-
macologic stress testing in conjunction with myo-
cardial perfusion imaging (1–4). The hope is that
the A2A receptor selectivity will reduce the side
effects that accompany the use of adenosine or
dipyridamole for pharmacologic stress, and possibly
allow safe use in those with reactive airways disease,
and, at the same time, provide similar imaging data
as nonspecific adenosine-receptor agonists do. Two
of these agents, regadenoson and binodenoson, are
well along in development, and in this issue of
JACC: Cardiovascular Imaging, the second pivotal
trial data for regadenoson are reported (3). The
investigators conclude that perfusion imaging with
regadenoson is noninferior with regard to the extent
of reversible defects produced compared with aden-
osine, and that side effects are reduced, which is
consistent with the A2A receptor selectivity.
See page 307
Do these agents work? Stimulation of adenosine
A2A receptors, given appropriate dosing, should
result in coronary arteriolar vasodilation, reduction
in coronary resistance, and, thus, in an increase in
coronary flow velocity and reserve. With that as a
metric, all 3 of the agents that have recently reached
human trials—regadenoson, binodenoson, and apo-
denoson—work well. They have all been studied
using coronary flow velocity or reserve measures in
patients undergoing catheterization, and all have
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the Division of Cardiology, Department of Medicine, Tufts
Medical Center, Boston, Massachusetts. Dr. Udelson is both a consultant
and the principal investigator for the binodenoson trial program, and he
has received compensation for his time from King Pharmaceuticals R&D.shown similar increments in coronary flow mea-
sures when compared to intracoronary adenosine
(5–7). Thus, they all clearly do what they are
supposed to do.
For regulatory purposes, however, these agents
must demonstrate efficacy when paired with the
tracers and imaging methodology that will accom-
pany them in clinical practice: in this case, radio-
nuclide perfusion tracers, single-photon emission
computed tomography (SPECT) imaging, and
some method of clinical analysis of those images.
Therein lies the rub.
Our repertoire of approaches to demonstrate
efficacy of any new imaging modality to a regulatory
standard is limited. Assessing sensitivity and spec-
ificity for detecting a certain threshold of anatomic
coronary disease is plagued by issues of referral bias,
among other problematic issues, such that a true
measure of performance is difficult to obtain. Thus,
development strategies regarding efficacy for rega-
denoson and binodenoson have focused on concor-
dance, the concept that the image data using the
new stress agent should provide clinically similar
imaging information as that derived from a stan-
dard approved agent, usually considered in these
trials to be adenosine.
When are 2 images concordant, and how do you
measure that objectively? When reading paired im-
ages side by side, say when comparing a patient’s
old SPECT or echo study with a new study,
experienced readers generally feel comfortable judg-
ing whether the new study is similar or different
when compared to the old study. However, where is
the border distinguishing similar and different? Our
perhaps arrogant “feeling” that we readers know
concordance or discordance when we see it does not
translate well into the clinical trial or regulatory
environment, where objective definitions need to be
specified clearly and prospectively. Moreover, side-
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318y-side reading, in the context of a trial examining
hether a new agent is similar to an approved
gent, is biased toward finding agreement.
With SPECT imaging, a semiquantitative seg-
ental scoring system for perfusion at stress and
est is usually incorporated, with the difference
etween the stress and rest scores representing
eversible defects on a segmental basis, and the
ummed difference score for the 17 segments giving
number that incorporates the extent and severity
f reversible defects (8). We like to believe that this
pproach is “validated,” insofar as there is a general
orrelation between the summed stress and the
ummed difference scores and various natural his-
ory outcome events during follow-up, based on the
xtensive literature (9). These scores are often
rouped into categories labeled normal, mild, mod-
rate, and severe to correspond to clinically relevant
omenclature. Thus, a sheen of objectivity is added
o the image analysis, though it remains the product
f a human eyeball endeavor.
he current study. In the current regadenoson study
3), patients had a clinically indicated adenosine
tudy and then were randomized to have a regade-
oson study or a second adenosine study within 4
eeks, in a 2:1 ratio. The stress and rest images
ere analyzed in a central core lab, with expert
eaders assigning segmental perfusion scores. A
egment was defined as reversible if it had a differ-
nce score of 1 (i.e., reversible did not distinguish
he severity of the defect). The investigators then
rouped the number of reversible segments into
ategories: none-to-minimal (0 or 1 reversible seg-
ents), small-to-moderate (2 to 4 reversible seg-
ents), or large (5 reversible segments), repre-
enting the extent of reversibility for the patient.
he hypothesis was that the agreement of patients’
denosine and regadenoson scans, defined as the
ercentage of patients who had similar categoriza-
ion of the extent of reversible defects for their
nitial adenosine and then their randomized rega-
enoson study, would be no worse (noninferior)
han the agreement that occurred when adenosine
cans were done twice. The resulting agreement
esults fell within the investigators’ pre-specified
oninferiority boundaries, thus the investigators
onsidered the trial positive for efficacy.
So from the investigators’ pre-specified perspec-
ive, the trial is positive. However, one could also
ay that 62% agreement, when the exact same
denosine test is done a second time, sets a low bar
or analyzing a new test. How did that modest
greement happen? We like to think that SPECT tmaging is reasonably reproducible, based on pub-
ished literature mostly emanating from single cen-
ers in small numbers of patients, using varying
nalytic methodologies (10–12). I think the data in
he current study has exposed some of the impor-
ant issues in how we analyze SPECT images for
linical trial purposes for any agent and, thus, is a
ery important contribution.
plitting and lumping. The imperative to categorize
esults to generate ordinal data for analytic purposes
ay actually create difference out of similarity.
iven the category cut points, it is possible that a
atient whose studies had 2 and 4 reversible defects
ould be labeled agreement, but another patient
hose 2 studies had 4 and 5 reversible defects
ould be labeled disagreement. This is simply a
onsequence of the need to impose arbitrary cut
oints. Thus, the agreement between regadenoson
nd adenosine may actually be better than as ana-
yzed by the investigators.
On the other hand, collapsing the segmental
ifference scores into reversible or not reversible per
egment (essentially making any severity of differ-
nce scores of 1, 2, 3, or 4 equivalent) masks
ariability in the scoring by minimizing the range of
cores being categorically compared. It also creates
ossibilities for the 2 studies from an individual
atient to theoretically be very different with regard
o the extent and severity of ischemia but be called
greement. A study with 2 segments with difference
cores of 2 (summed score  4) would be consid-
red to agree with a second study with 4 segments
ith a difference score of 4 (summed score  16),
ecause both fall into the 2-to-4-reversible-
egments category, though the full extent and se-
erity of reversible defects (reflected by the summed
ifference scores) is not at all similar. Hence, the
nalytic lumping method leaves open the possibility
hat the agents’ efficacy may not be similar. Because
he catheterization lab flow studies show a similar
ncrement in coronary flow with regadenoson com-
ared with adenosine (5), dissimilarity of efficacy is
ot likely to be the case. However, the analytic
pproach for the primary agreement end point in
his analysis may not be conclusive on this point
ecause of these issues, which could apply to any
ew SPECT imaging agent.
nalytic variability and the need for quantitation. The
denosine–adenosine data illustrate the variability
hat ensues when humans (even highly expert hu-
ans) assign semiquantitative scores to a 17-
egment model for 2 separate SPECT studies from
he same patient, in a rigorous analytic environment
t
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319hat must be in keeping with the Food and Drug
dministration’s (FDA) guidance document for
maging in clinical trials (13).
There are many potential sources of variability,
ncluding biologic variability of coronary flow re-
ponse to adenosine-receptor stimulation and ac-
uisition variables. However, it is likely that human
ariability in assigning the segmental scores plays a
arge role. Intra- and inter-reader reproducibility
ata are not reported for this data set to help
nderstand that element. Other modalities also
ave substantial variability when rigorously ana-
yzed (14,15). The potential advantage of radionu-
lide imaging is its inherently digital nature, which
ends itself to more objective quantitation. Why was
utomated quantitative analysis not used here? In-
eed, in the regadenoson phase 2 published study
16), agreement with adenosine was better with
uantitative analysis compared with the human
nalysis. Quantitative programs are almost univer-
ally available and, although not without flaws,
ould at least remove the human variability element
nd possibly would have allowed the investigators to
ore closely approach the truth of potential con-
ordance of the new agent compared with the old.
ide effects. Consistent with regadenoson’s degree
f selectivity for the A2A receptor, the investigators
eport a modest reduction in some of the common
ide effects of adenosine testing. Of the 3 most
ommon, chest pain and flushing were lower, and
yspnea was numerically greater with regadenoson
n what appears to be a combined analysis from the
 pivotal trials. In the previously reported initial
ivotal trial (4), dyspnea prevalence was higher with
egadenoson. Overall, in the combined analysis, a
atient tolerability score favored regadenoson (p 
.05). The investigators do not clearly state how the
 major nor the 7 total side effect categories were to
e analyzed; they also do not indicate whether their
pproach called for corrections for multiple testing.
t is stated that a pre-defined composite severity
core was calculated for chest pain, dyspnea, and
ushing, and this favored regadenoson, but it is not
tated whether this score was a patient or a physi-
ian assessment. The strength of this finding isselective A(2A) adenosine receptor et al. Randomizedte result is strongest when all of its components
ove in a directionally similar manner (17) and that
he comparative data emanate from different pa-
ients in this parallel design study.
onclusions. Based on the coronary flow data alone,
t appears that regadenoson, binodenoson, and apo-
enoson all result in the expected and adequate
ncrease in coronary flow when administered intra-
enously (5–7) and, thus, should be efficacious as
harmacologic stress agents for SPECT imaging.
he problem well illustrated by the 2 published
ivotal trials of regadenoson is related to analytic
ethodology of SPECT perfusion images, in that a
ignal of concordance is hard to discern because of
he noise incurred by segmental human scoring and
he splitting and lumping of the resultant numerical
ata. This would likely be no different if binodeno-
on or apodenoson had been the agent under study
sing these methods. It is unfortunate that quanti-
ation was not used, as that would have introduced
ome objectivity into the analysis and removed at
east 1 source of variability (at least theoretically).
It is important to note, however, that the role of
ully automated quantitative analysis in a develop-
ent program for a new imaging agent (at least for
ardiac purposes) is not clearly defined in the FDA’s
uidance documents, and thus, commercial spon-
ors of new agents are appropriately wary of relying
oo heavily on that method. The most important
esson to be learned here is that it is time for the
merican College of Cardiology, the American
ociety of Nuclear Cardiology, and our other im-
ging society colleagues to engage with the FDA to
ritically assess analytic methodology for cardiac
maging, with an eye toward incorporating quanti-
ative methods appropriately into future FDA guid-
nce documents. All cardiovascular imaging fields
ould benefit, and the development of new agents
ould be facilitated without the distraction and
elay engendered by individual sponsors trying to
gure out how best to analyze images.
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